Close

Form 6-K NeuroSense Therapeutics For: Feb 08

February 8, 2023 9:19 AM EST


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of February 2023

 

Commission File Number: 001-41084

 

NeuroSense Therapeutics Ltd.

(Translation of registrant’s name into English)

 

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-799-6183
(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

On February 8, 2023, NeuroSense Therapeutics Ltd. (the “Company”) issued a press release announcing that Germany’s Federal Institute for Drugs and Medical Devices (BfArM) approved the Company’s Clinical Trial Application (CTA) to enroll patients in PARADIGM, its Phase 2b study of its lead combination drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS). A copy of the press release is filed herewith as Exhibit 99.1.

 

Exhibit Index

 

Exhibit No.   Description
99.1   Press Release, dated February 8, 2023

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NeuroSense Therapeutics Ltd.
     
Date: February 8, 2023 By: /s/ Alon Ben-Noon
    Alon Ben-Noon
    Chief Executive Officer

 

 

2

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE, DATED FEBRUARY 8, 2023



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings